REFERENCES
1. Grünewald TG, Alonso M, Avnet S, et al. Sarcoma treatment in the era of molecular medicine. EMBO Mol Med 2020;12:e11131.
2. Brown HK, Schiavone K, Gouin F, Heymann MF, Heymann D. Biology of bone sarcomas and new therapeutic developments. Calcif Tissue Int 2018;102:174-95.
3. Baumhoer D, Böhling TO, Cates JMM, et al. . Osteosarcoma. WHO Classification of Tumours Editorial board. Soft tissue and bone tumours. Lyon (France): International Agency for Research on Cancer; 2020. p. 403-9.
4. Flanagan AM, Bridge JA, O’Donnel PG. . Secondary osteosarcoma. WHO Classification of Tumours Editorial board. Soft tissue and bone tumours. Lyon (France): International Agency for Research on Cancer; 2020. p. 419-21.
7. Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 Suppl 7:vii100-9.
8. Kovac M, Blattmann C, Ribi S, et al. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nat Commun 2015;6:8940.
9. Behjati S, Tarpey PS, Haase K, et al. Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nat Commun 2017;8:15936.
10. Wu SP, Cooper BT, Bu F, et al. DNA methylation-based classifier for accurate molecular diagnosis of bone sarcomas. JCO Precis Oncol 2017:2017.
11. Morrow JJ, Bayles I, Funnell APW, et al. Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. Nat Med 2018;24:176-85.
12. Asano N, Takeshima H, Yamashita S, et al. Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas. Sci Rep 2019;9:20360.
13. Brown HK, Tellez-Gabriel M, Cartron PF, Vallette FM, Heymann MF, Heymann D. Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality? Drug Discov Today 2019;24:763-72.
14. Tellez-Gabriel M, Heymann MF, Heymann D. Circulating tumor cells as a tool for assessing tumor heterogeneity. Theranostics 2019;9:4580-94.
15. Vallette FM, Olivier C, Lézot F, et al. Dormant, quiescent, tolerant and persister cells: four synonyms for the same target in cancer. Biochem Pharmacol 2019;162:169-76.
16. Nassar D, Blanpain C. Cancer stem cells: basic concepts and therapeutic implications. Annu Rev Pathol 2016;11:47-76.
17. Walcher L, Kistenmacher AK, Suo H, et al. Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies. Front Immunol 2020;11:1280.
18. Clarke MF. Clinical and therapeutic implications of cancer stem cells. N Engl J Med 2019;380:2237-45.
19. Halldorsson A, Brooks S, Montgomery S, Graham S. Lung metastasis 21 years after initial diagnosis of osteosarcoma: a case report. J Med Case Rep 2009;3:9298.
20. Perrot P, Rousseau J, Bouffaut AL, et al. Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence. PLoS One 2010;5:e10999.
21. Pantel K, Alix-Panabières C. Tumour microenvironment: informing on minimal residual disease in solid tumours. Nat Rev Clin Oncol 2017;14:325-6.
22. Ferrari S, Bacci G, Picci P, et al. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol 1997;8:765-71.
23. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-90.
24. Smeland S, Bielack SS, Whelan J, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer 2019;109:36-50.
25. Pennati A, Riggio E, Marano G, Biganzoli E. Autologous fat grafting after sarcoma surgery: evaluation of oncological safety. J Plast Reconstr Aesthet Surg 2018;71:1723-9.
26. Le Nail LR, Brennan M, Rosset P, et al. Comparison of tumor- and bone marrow-derived mesenchymal stromal/stem cells from patients with high-grade osteosarcoma. Int J Mol Sci 2018;19:707.
27. Zhou Z, Li Y, Kuang M, et al. The CD24+ cell subset promotes invasion and metastasis in human osteosarcoma. EBioMedicine 2020;51:102598.
28. Shao XJ, Xiang SF, Chen YQ, et al. Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells. Acta Pharmacol Sin 2019;40:1343-50.
29. Adhikari AS, Agarwal N, Wood BM, et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 2010;70:4602-12.
30. Tang QL, Liang Y, Xie XB, et al. Enrichment of osteosarcoma stem cells by chemotherapy. Chin J Cancer 2011;30:426-32.
31. Yu L, Liu S, Zhang C, et al. Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity. Oncotarget 2013;4:2326-38.
32. Tirino V, Desiderio V, d’Aquino R, et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 2008;3:e3469.
33. Tirino V, Desiderio V, Paino F, et al. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J 2011;25:2022-30.
34. He A, Qi W, Huang Y, et al. CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: a clinical and experimental study. Exp Ther Med 2012;4:435-41.
35. Li J, Zhong XY, Li ZY, et al. CD133 expression in osteosarcoma and derivation of CD133+ cells. Mol Med Rep 2013;7:577-84.
36. Ozturk S, Gorgun C, Gokalp S, Vatansever S, Sendemir A. Development and characterization of cancer stem cell-based tumoroids as an osteosarcoma model. Biotechnol Bioeng 2020;117:2527-39.
37. Fujiwara T, Katsuda T, Hagiwara K, et al. Clinical relevance and therapeutic significance of microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells. Stem Cells 2014;32:959-73.
38. Mardani A, Gheytanchi E, Mousavie SH, Madjd Jabari Z, Shooshtarizadeh T. Clinical significance of cancer stem cell markers CD133 and CXCR4 in osteosarcomas. Asian Pac J Cancer Prev 2020;21:67-73.
39. Bao Z, Cheng Z, Chai D. The expressions of CD133, ALDH1, and vasculogenic mimicry in osteosarcoma and their clinical significance. Int J Clin Exp Pathol 2018;11:3656-63.
40. Tian J, Li X, Si M, Liu T, Li J. CD271+ osteosarcoma cells display stem-like properties. PLoS One 2014;9:e98549.
41. Honoki K, Fujii H, Kubo A, et al. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol Rep 2010;24:501-5.
42. Wang L, Park P, Zhang H, La Marca F, Lin CY. Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int J Cancer 2011;128:294-303.
43. Martins-Neves SR, Paiva-Oliveira DI, Wijers-Koster PM, et al. Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/β-catenin signaling. Cancer Lett 2016;370:286-95.
44. Wang F, Zhang Z, Li Q, Yu T, Ma C. Untargeted LC-MS/MS analysis reveals metabolomics feature of osteosarcoma stem cell response to methotrexate. Cancer Cell Int 2020;20:269.
45. Mizushima E, Tsukahara T, Emori M, et al. Osteosarcoma-initiating cells show high aerobic glycolysis and attenuation of oxidative phosphorylation mediated by LIN28B. Cancer Sci 2020;111:36-46.
46. Zhong Z, Mao S, Lin H, Li H, Lin J, Lin JM. Alteration of intracellular metabolome in osteosarcoma stem cells revealed by liquid chromatography-tandem mass spectrometry. Talanta 2019;204:6-12.
47. Koka P, Mundre RS, Rangarajan R, Chandramohan Y, Subramanian RK, Dhanasekaran A. Uncoupling Warburg effect and stemness in CD133+ve cancer stem cells from Saos-2 (osteosarcoma) cell line under hypoxia. Mol Biol Rep 2018;45:1653-62.
48. Pozzi V, Salvolini E, Lucarini G, et al. Cancer stem cell enrichment is associated with enhancement of nicotinamide N-methyltransferase expression. IUBMB Life 2020;72:1415-25.
49. Wang Y, Zeng L, Liang C, et al. Integrated analysis of transcriptome-wide m6A methylome of osteosarcoma stem cells enriched by chemotherapy. Epigenomics 2019;11:1693-715.
50. Menéndez ST, Gallego B, Murillo D, Rodríguez A, Rodríguez R. Cancer stem cells as a source of drug resistance in bone sarcomas. J Clin Med 2021;10:2621.
51. Belayneh R, Weiss K. . The role of aldh in the metastatic potential of osteosarcoma cells and potential ALDH targets. In: Kleinerman ES, Gorlick R, editors. Current advances in the science of osteosarcoma. Cham: Springer International Publishing; 2020. p. 157-66.
52. Tsuchida R, Das B, Yeger H, et al. Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling. Oncogene 2008;27:3923-34.
53. Sun DX, Liao GJ, Liu KG, Jian H. Endosialin-expressing bone sarcoma stem-like cells are highly tumor-initiating and invasive. Mol Med Rep 2015;12:5665-70.
54. Di Fiore R, Santulli A, Ferrante RD, et al. Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment. J Cell Physiol 2009;219:301-13.
55. Roundhill EA, Chicon-Bosch M, Jeys L, et al. RNA sequencing and functional studies of patient-derived cells reveal that neurexin-1 and regulators of this pathway are associated with poor outcomes in Ewing sarcoma. Cell Oncol (Dordr) 2021;44:1065-85.
56. Alfranca A, Martinez-Cruzado L, Tornin J, et al. Bone microenvironment signals in osteosarcoma development. Cell Mol Life Sci 2015;72:3097-113.
57. Danieau G, Morice S, Rédini F, et al. New insights about Wnt/beta-catenin signaling pathway in primary bone tumors and their microenvironment: a promising target to develop therapeutic strategies? Int J Mol Sci 2019;20:3751.
58. Deng Q, Li P, Che M, et al. Activation of hedgehog signaling in mesenchymal stem cells induces cartilage and bone tumor formation via Wnt/β-Catenin. Elife 2019;8:e50208.
59. Parsons MJ, Tammela T, Dow LE. WNT as a driver and dependency in cancer. Cancer Discov 2021;11:2413-29.
60. Martins-Neves SR, Corver WE, Paiva-Oliveira DI, et al. Osteosarcoma stem cells have active Wnt/β-catenin and overexpress SOX2 and KLF4. J Cell Physiol 2016;231:876-86.
61. Martins-Neves SR, Cleton-Jansen AM, Gomes CMF. Therapy-induced enrichment of cancer stem-like cells in solid human tumors: where do we stand? Pharmacol Res 2018;137:193-204.
62. Zhang RM, Tang T, Yu HM, et al. LncRNA DLX6-AS1/miR-129-5p/DLK1 axis aggravates stemness of osteosarcoma through Wnt signaling. Biochem Biophys Res Commun 2018;507:260-6.
63. Jiang C, He C, Wu Z, Li F, Xiao J. Histone methyltransferase SETD2 regulates osteosarcoma cell growth and chemosensitivity by suppressing Wnt/β-catenin signaling. Biochem Biophys Res Commun 2018;502:382-8.
64. Blanchard F, Duplomb L, Baud’huin M, Brounais B. The dual role of IL-6-type cytokines on bone remodeling and bone tumors. Cytokine Growth Factor Rev 2009;20:19-28.
65. Cortini M, Massa A, Avnet S, Bonuccelli G, Baldini N. Tumor-activated mesenchymal stromal cells promote osteosarcoma stemness and migratory potential via IL-6 secretion. PLoS One 2016;11:e0166500.
66. Tu B, Zhu J, Liu S, et al. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3. Oncotarget 2016;7:48296-308.
67. Baglio SR, Lagerweij T, Pérez-Lanzón M, et al. Blocking tumor-educated MSC paracrine activity halts osteosarcoma progression. Clin Cancer Res 2017;23:3721-33.
68. Zhang C, Ma K, Li WY. Cinobufagin suppresses the characteristics of osteosarcoma cancer cells by inhibiting the IL-6-OPN-STAT3 Pathway. Drug Des Devel Ther 2019;13:4075-90.
69. Tian ZC, Wang JQ, Ge H. Apatinib ameliorates doxorubicin-induced migration and cancer stemness of osteosarcoma cells by inhibiting Sox2 via STAT3 signalling. J Orthop Translat 2019;22:132-41.
70. Zhang H, Wu H, Zheng J, et al. Transforming growth factor β1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma. Stem Cells 2013;31:433-46.
71. Ma K, Zhang C, Li W. Gamabufotalin suppressed osteosarcoma stem cells through the TGF-β/periostin/PI3K/AKT pathway. Chem Biol Interact 2020;331:109275.
72. Wang T, Wang D, Zhang L, et al. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells. J Exp Clin Cancer Res 2019;38:226.
73. Maurizi G, Verma N, Gadi A, Mansukhani A, Basilico C. Sox2 is required for tumor development and cancer cell proliferation in osteosarcoma. Oncogene 2018;37:4626-32.
74. Chen Y, Wang T, Huang M, et al. MAFB promotes cancer stemness and tumorigenesis in osteosarcoma through a Sox9-mediated positive feedback loop. Cancer Res 2020;80:2472-83.
75. Subramaniam D, Angulo P, Ponnurangam S, et al. Suppressing STAT5 signaling affects osteosarcoma growth and stemness. Cell Death Dis 2020;11:149.
76. Fan H, Liu G, Zhao C, Li X, Yang X. Transcription factor Oct4 promotes osteosarcoma by regulating lncRNA AK055347. Oncol Lett 2017;13:396-402.
77. Xi X, Wu Q, Bao Y, et al. Overexpression of TBL1XR1 confers tumorigenic capability and promotes recurrence of osteosarcoma. Eur J Pharmacol 2019;844:259-67.
78. Chen X, Zhang Q, Dang X, et al. Targeting the CtBP1-FOXM1 transcriptional complex with small molecules to overcome MDR1-mediated chemoresistance in osteosarcoma cancer stem cells. J Cancer 2021;12:482-97.
79. Fan GT, Ling ZH, He ZW, Wu SJ, Zhou GX. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma. Biochem Biophys Res Commun 2021;554:214-21.
80. Gan Z, Han K, Lin S, Hu H, Shen Z, Min D. Knockdown of ubiquitin-specific peptidase 39 inhibited the growth of osteosarcoma cells and induced apoptosis in vitro. Biol Res 2017;50:15.
81. Xu W, Chen C, Xu R, et al. Knockdown of HuR represses osteosarcoma cells migration, invasion and stemness through inhibition of YAP activation and increases susceptibility to chemotherapeutic agents. Biomed Pharmacother 2018;102:587-93.
82. Li S, Bai H, Chen X, et al. Soft substrate promotes osteosarcoma cell self-renewal, differentiation, and drug resistance through miR-29b and its target protein spin 1. ACS Biomater Sci Eng 2020;6:5588-98.
83. Zou Y, Huang Y, Yang J, Wu J, Luo C. miR-34a is downregulated in human osteosarcoma stem-like cells and promotes invasion, tumorigenic ability and self-renewal capacity. Mol Med Rep 2017;15:1631-7.
84. Liang X, Xu C, Wang W, Li X. The DNMT1/miR-34a axis is involved in the stemness of human osteosarcoma cells and derived stem-like cells. Stem Cells Int 2019;2019:7028901.
85. Liang X, Xu C, Cao X, Wang W. Isovitexin suppresses cancer stemness property and induces apoptosis of osteosarcoma cells by disruption of the DNMT1/miR-34a/Bcl-2 axis. Cancer Manag Res 2019;11:8923-36.
86. Yao J, Lin J, He L, Huang J, Liu Q. TNF-α/miR-155 axis induces the transformation of osteosarcoma cancer stem cells independent of TP53INP1. Gene 2020;726:144224.
87. Guo X, Yu L, Zhang Z, Dai G, Gao T, Guo W. miR-335 negatively regulates osteosarcoma stem cell-like properties by targeting POU5F1. Cancer Cell Int 2017;17:29.
88. Zhang L, Yang P, Liu Q, et al. KLF8 promotes cancer stem cell-like phenotypes in osteosarcoma through miR-429-SOX2 signaling. Neoplasma 2020;67:519-27.
89. Lavaud M, Georges S, Ory B. . MircoRNA implication in therapeutic resistance and metastatic dissemination of bone-associated tumors. In: Heymann D, editor. Bone cancer: bone sarcomas and bone metastases - from bench to bedside. Academic Press; 2022. p. 447-56.
90. Qu Y, Zheng S, Kang M, et al. Knockdown of long non-coding RNA HOXD-AS1 inhibits the progression of osteosarcoma. Biomed Pharmacother 2018;98:899-906.
91. Lu B, He Y, He J, et al. Epigenetic profiling identifies LIF as a super-enhancer-controlled regulator of stem cell-like properties in osteosarcoma. Mol Cancer Res 2020;18:57-67.
92. Yan GN, Tang XF, Zhang XC, et al. TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway. Oncotarget 2017;8:85628-41.
93. He J, Ling L, Liu Z, et al. Functional interplay between long non-coding RNAs and the Wnt signaling cascade in osteosarcoma. Cancer Cell Int 2021;21:313.
94. Camuzard O, Trojani MC, Santucci-Darmanin S, et al. Autophagy in osteosarcoma cancer stem cells is critical process which can be targeted by the antipsychotic drug thioridazine. Cancers (Basel) 2020;12:3675.
95. Zhang D, Zhao Q, Sun H, et al. Defective autophagy leads to the suppression of stem-like features of CD271+ osteosarcoma cells. J Biomed Sci 2016;23:82.
96. Wang JH, Gong C, Guo FJ, et al. Knockdown of STIP1 inhibits the invasion of CD133-positive cancer stem-like cells of the osteosarcoma MG63 cell line via the PI3K/Akt and ERK1/2 pathways. Int J Mol Med 2020;46:2251-9.
97. Shu X, Liu H, Zhen R, et al. Hsp90 inhibitor 17-AAG inhibits stem cell-like properties and chemoresistance in osteosarcoma cells via the Hedgehog signaling pathway. Oncol Rep 2020;44:313-24.
98. Hua Y, Jia X, Sun M, et al. Plasma membrane proteomic analysis of human osteosarcoma and osteoblastic cells: revealing NDRG1 as a marker for osteosarcoma. Tumour Biol 2011;32:1013-21.
99. Chano T, Kita H, Avnet S, Lemma S, Baldini N. Prominent role of RAB39A-RXRB axis in cancer development and stemness. Oncotarget 2018;9:9852-66.
100. Takahashi N, Nobusue H, Shimizu T, et al. ROCK inhibition induces terminal adipocyte differentiation and suppresses tumorigenesis in chemoresistant osteosarcoma cells. Cancer Res 2019;79:3088-99.
101. Liu F, Li L, Li Y, et al. Overexpression of SENP1 reduces the stemness capacity of osteosarcoma stem cells and increases their sensitivity to HSVtk/GCV. Int J Oncol 2018; doi: 10.3892/ijo.2018.4537.
102. Tang ML, Bai XJ, Li Y, Dai XJ, Yang F. MMP-1 Over-expression promotes malignancy and stem-like properties of human osteosarcoma MG-63 cells in vitro. Curr Med Sci 2018;38:809-17.
103. Zhao T, Meng Y, Wang Y, Wang W. NDRG1 regulates osteosarcoma cells via mediating the mitochondrial function and CSCs differentiation. J Orthop Surg Res 2021;16:364.
104. Feng J, Lan R, Cai G, Lin J. TREX1 suppression imparts cancer-stem-cell-like characteristics to CD133- osteosarcoma cells through the activation of E2F4 signaling. Int J Clin Exp Pathol 2019;12:1134-53.
105. Martins-Neves SR, Paiva-Oliveira DI, Fontes-Ribeiro C, Bovée JVMG, Cleton-Jansen AM, Gomes CMF. IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft. Cancer Lett 2018;414:1-15.
106. Nomura M, Rainusso N, Lee YC, et al. Tegavivint and the β-catenin/ALDH axis in chemotherapy-resistant and metastatic osteosarcoma. J Natl Cancer Inst 2019;111:1216-27.
107. Liu W, Zhao Z, Wang Y, et al. Dioscin inhibits stem-cell-like properties and tumor growth of osteosarcoma through Akt/GSK3/β-catenin signaling pathway. Cell Death Dis 2018;9:343.
108. Wei D, Zhu X, Li S, et al. Tideglusib suppresses stem-cell-like features and progression of osteosarcoma by inhibiting GSK-3β/NOTCH1 signaling. Biochem Biophys Res Commun 2021;554:206-13.
109. Wang H, Zhang C, Xu L, et al. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway. Oncotarget 2016;7:20193-208.
110. Xiong Q, Wang X, Wang L, et al. BMP-2 inhibits lung metastasis of osteosarcoma: an early investigation using an orthotopic model. Onco Targets Ther 2018;11:7543-53.
111. Wang S, Hu H, Zhong B, et al. Bruceine D inhibits tumor growth and stem cell-like traits of osteosarcoma through inhibition of STAT3 signaling pathway. Cancer Med 2019;8:7345-58.
112. Gonçalves JM, Silva CAB, Rivero ERC, Cordeiro MMR. Inhibition of cancer stem cells promoted by Pimozide. Clin Exp Pharmacol Physiol 2019;46:116-25.
113. Lillo Osuna MA, Garcia-Lopez J, El Ayachi I, et al. Activation of estrogen receptor alpha by decitabine inhibits osteosarcoma growth and metastasis. Cancer Res 2019;79:1054-68.
114. Hirozane T, Masuda M, Sugano T, et al. Direct conversion of osteosarcoma to adipocytes by targeting TNIK. JCI Insight 2021;6:137245.
115. Qu H, Xue Y, Lian W, et al. Melatonin inhibits osteosarcoma stem cells by suppressing SOX9-mediated signaling. Life Sci 2018;207:253-64.
116. Li Y, Xian M, Yang B, Ying M, He Q. Inhibition of KLF4 by statins reverses Adriamycin-induced metastasis and cancer stemness in osteosarcoma cells. Stem Cell Reports 2017;8:1617-29.
117. Deguchi T, Hosoya K, Kim S, et al. Metformin preferentially enhances the radio-sensitivity of cancer stem-like cells with highly mitochondrial respiration ability in HMPOS. Mol Ther Oncolytics 2021;22:143-51.
118. Shang D, Wu J, Guo L, Xu Y, Liu L, Lu J. Metformin increases sensitivity of osteosarcoma stem cells to cisplatin by inhibiting expression of PKM2. Int J Oncol 2017;50:1848-56.
119. Zhao B, Luo J, Wang Y, et al. Metformin suppresses self-renewal ability and tumorigenicity of osteosarcoma stem cells via reactive oxygen species-mediated apoptosis and autophagy. Oxid Med Cell Longev 2019;2019:9290728.
120. Paiva-Oliveira DI, Martins-Neves SR, Abrunhosa AJ, Fontes-Ribeiro C, Gomes CMF. Therapeutic potential of the metabolic modulator Metformin on osteosarcoma cancer stem-like cells. Cancer Chemother Pharmacol 2018;81:49-63.
121. Koh H, Sun HN, Xing Z, et al. Wogonin influences osteosarcoma stem cell stemness through ROS-dependent signaling. In Vivo 2020;34:1077-84.
122. Ba G, Hua Z, Xu N, et al. Novel agent DMAMCL suppresses osteosarcoma growth and decreases the stemness of osteosarcoma stem cell. Cell Cycle 2020;19:1530-44.
123. Dai G, Deng S, Guo W, et al. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma. Mol Carcinog 2019;58:3-18.
124. Oka N, Komuro A, Amano H, et al. Ascorbate sensitizes human osteosarcoma cells to the cytostatic effects of cisplatin. Pharmacol Res Perspect 2020;8:e00632.
125. Guo W, Wei B, Cheng T, Xu X, Ruan F, Xiang M. The Na+/K+ ATPase inhibitor ouabain attenuates stemness and chemoresistance of osteosarcoma cells. Med Sci Monit 2019;25:9426-34.
126. Gurunathan S, Jeyaraj M, Kang MH, Kim JH. Tangeretin-assisted platinum nanoparticles enhance the apoptotic properties of doxorubicin: combination therapy for osteosarcoma treatment. Nanomaterials (Basel) 2019;9:1089.
127. Ferreira de Oliveira JMP, Pacheco AR, Coutinho L, et al. Combination of etoposide and fisetin results in anti-cancer efficiency against osteosarcoma cell models. Arch Toxicol 2018;92:1205-14.
128. Heymann MF, Schiavone K, Heymann D. Bone sarcomas in the immunotherapy era. Br J Pharmacol 2021;178:1955-72.
129. Mesiano G, Grignani G, Fiorino E, et al. Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy. Oncoimmunology 2018;7:e1465161.
130. Wang W, Chen D, Zhu K. SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition. J Exp Clin Cancer Res 2018;37:37.
131. Lu SL, Wang YH, Liu GF, et al. Graphene oxide nanoparticle-loaded ginsenoside Rg3 improves photodynamic therapy in inhibiting malignant progression and stemness of osteosarcoma. Front Mol Biosci 2021;8:663089.
132. Tian J, Gu Y, Li Y, Liu T. CD271 antibody-functionalized HGNs for targeted photothermal therapy of osteosarcoma stem cells. Nanotechnology 2020;31:305707.
133. Mineo PG, Foti C, Vento F, et al. Salinomycin-loaded PLA nanoparticles: drug quantification by GPC and wave voltammetry and biological studies on osteosarcoma cancer stem cells. Anal Bioanal Chem 2020;412:4681-90.
134. Gui K, Zhang X, Chen F, et al. Lipid-polymer nanoparticles with CD133 aptamers for targeted delivery of all-trans retinoic acid to osteosarcoma initiating cells. Biomed Pharmacother 2019;111:751-64.
135. Chen F, Zeng Y, Qi X, et al. Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells. Nanomedicine 2018;14:2115-27.
136. Gambera S, Abarrategi A, González-Camacho F, et al. Clonal dynamics in osteosarcoma defined by RGB marking. Nat Commun 2018;9:3994.
137. Tellez-Gabriel M, Cochonneau D, Cadé M, Jubellin C, Heymann MF, Heymann D. Circulating tumor cell-derived pre-clinical models for personalized medicine. Cancers (Basel) 2018;11:19.
138. Zhang W, Zhao JM, Lin J, et al. Adaptive fibrogenic reprogramming of osteosarcoma stem cells promotes metastatic growth. Cell Rep 2018;24:1266-77.e5.
139. Heymann MF, Lézot F, Heymann D. The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma. Cell Immunol 2019;343:103711.
140. Avnet S, Lemma S, Cortini M, et al. The release of inflammatory mediators from acid-stimulated mesenchymal stromal cells favours tumour invasiveness and metastasis in osteosarcoma. Cancers (Basel) 2021;13:5855.
141. Avnet S, Lemma S, Cortini M, Di Pompo G, Perut F, Baldini N. Pre-clinical models for studying the interaction between mesenchymal stromal cells and cancer cells and the induction of stemness. Front Oncol 2019;9:305.
142. Bonuccelli G, Avnet S, Grisendi G, et al. Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells. Oncotarget 2014;5:7575-88.
